Tumor-Induced Osteomalacia

Patients with both X-linked hypophosphatemia and tumor-induced osteomalacia can benefit from phosphorus replacement therapy, according to two presentations at the United Rheumatology Spring Virtual conference.

In June, the FDA approved burosumab for a second rare bone disease, expanded the indication for an interoperable insulin pump, cleared an integrated continuous glucose monitor, and approved a biosimilar and a new faster-acting insulin. 

The FDA approved burosumab-twza injection to treat patients aged 2 years and older with tumor-induced osteomalacia, according to an agency press release.

A small cohort of adults with tumor-induced osteomalacia experienced improvements in phosphate and skeletal metabolism, physical functioning and quality of life after 144 weeks of treatment with burosumab therapy, study data show.